Phillip Palmbos is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 160 publications with 2,714 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Registry record last updated 22 Apr 2019.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20231 payment$18,182openpaymentsdata.cms.gov ↗
- Genentech, Inc.Program year20221 payment$18,750openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48%Cytochrome P450 17A1 Inhibitor34.4%Abiraterone Acetate100%Part D≥24 patientsAndrogen Receptor Inhibitor13.6%Xtandi100%Part D<11 patientsMetabolism & gastrointestinal
24%Corticosteroid24%Prednisone100%Part D≥23 patientsNervous system
12.1%Gabapentinoids4.3%Gabapentin100%Part D<11 patientsPhenothiazine4.3%Prochlorperazine Maleate100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2016–2026 per NIH RePORTER. The latest:
- Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder Cancer
University of Michigan at Ann Arbor
FY2026$438,648R37CA273138 - Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder Cancer
University of Michigan at Ann Arbor
FY2025$442,533R37CA273138 - Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder Cancer
University of Michigan at Ann Arbor
FY2024$429,017R37CA273138
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”